STOCK TITAN
  1. Home
  2. News
  3. MRK

Merck & Co., Inc. - MRK STOCK NEWS

Welcome to our dedicated page for Merck & Co. news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co. stock.

Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, is a renowned American multinational pharmaceutical company headquartered in Rahway, New Jersey. Originally the American arm of Germany's Merck Group founded in 1668, Merck has established itself as a global leader in pharmaceuticals and vaccines.

Merck's core business is the development and manufacturing of medications and vaccines spanning several therapeutic areas such as cardiometabolic diseases, cancer, and infections. The company's immuno-oncology platform, particularly strong in cancer treatment, is a significant revenue driver. The firm’s oncology portfolio includes groundbreaking immunotherapies like KEYTRUDA, designed to treat melanoma and other cancers. KEYTRUDA, in combination with other therapies, has shown promising results in reducing cancer recurrence and improving survival rates.

Merck also boasts a robust vaccine business, offering vaccines for pediatric diseases and human papillomavirus (HPV). Their commitment to public health extends to Merck for Mothers, an initiative aimed at improving maternal health globally. In 2024, Merck surpassed its goal early by reaching over 30 million women with programs promoting safe, high-quality maternal care.

The company's animal health division is another sector of its diverse operations, providing solutions to improve animal health and productivity.

From a geographical perspective, nearly half of Merck's sales are generated in the United States. Financially, Merck maintains a solid position with ongoing investments in research and development to fuel innovation. The company is actively engaged in numerous partnerships and collaborative research initiatives to accelerate the development of new therapies.

Merck’s mission is rooted in scientific excellence and an unwavering commitment to improving lives. The company continues to invest in leading-edge research, with over 2,250 ongoing clinical trials, including more than 1,600 trials evaluating combination regimens. This dedication underpins Merck's strategy to address complex health challenges and advance global health.

News

Merck Ranks No. 1 on Newsweek’s List of America’s Most Responsible Companies 2024

Rhea-AI Summary
Merck (NYSE:MRK) has been recognized as America's Most Responsible Company by Newsweek, securing the top spot for the first time and achieving a perfect score of 100/100 in corporate governance. This marks the second consecutive year that Merck has been acknowledged as an industry leader, highlighting its commitment to responsible business practices. The company's chairman and CEO, Robert M. Davis, expressed pride in this recognition, emphasizing Merck's dedication to enabling a safe and healthy future for people and communities globally. Merck's achievements on multiple esteemed lists, including CNBC and JUST Capital's Most JUST Companies and Barron's 100 Most Sustainable U.S. Companies, further solidify its reputation as a leader in corporate responsibility and sustainability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
none
-
News

Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer

Rhea-AI Summary
Merck (MRK) and Moderna (MRNA) have initiated the second clinical trial in the INTerpath program, a Phase 3 randomized clinical trial evaluating V940 (mRNA-4157) in combination with KEYTRUDA as adjuvant treatment in patients with completely resected non-small cell lung cancer. This represents a rapid expansion in research for individualized neoantigen therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
clinical trial
-
News

Merck Animal Health Receives Positive CVMP Opinion for an Injectable Formulation of BRAVECTO® (Fluralaner) for Use in Dogs

Rhea-AI Summary
Merck Animal Health (NYSE:MRK) announced that the European Medicines Agency's Committee for Veterinary Medicinal Products issued a positive opinion for BRAVECTO, an injectable formulation for the treatment and persistent killing of fleas and ticks in dogs. If approved by the European Commission, this once-yearly medication will provide long-lasting protection for pets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
none
News

Merck and Eisai Provide Update on Phase 3 LEAP-001 Trial Evaluating (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

Rhea-AI Summary
Merck (MRK) and Eisai Announce Disappointing Results for KEYTRUDA Plus LENVIMA in Phase 3 LEAP-001 Trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
clinical trial
-
News

Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LYNPARZA® (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility

Rhea-AI Summary
Merck (MRK) stops Phase 3 KEYLYNK-008 trial for KEYTRUDA and LYNPARZA combination in metastatic squamous NSCLC due to lack of improvement in overall survival. KEYTRUDA-based combinations in NSCLC are being evaluated in other studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.66%
Tags
none
-
News

Merck Announces Findings from Phase 2 KeyVibe-002 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)

Rhea-AI Summary
Merck (MRK) presented full results from the non-registrational Phase 2 KeyVibe-002 trial at ESMO I-O 2023 Annual Meeting. The trial evaluated vibostolimab/pembrolizumab, an investigational coformulation, for metastatic non-small cell lung cancer patients. The coformulation, with or without docetaxel, extended median progression-free survival by 2.4 months compared to docetaxel alone. However, the results did not reach statistical significance. Vibostolimab/pembrolizumab alone did not show an improvement in median PFS compared to docetaxel alone. Key secondary endpoints, including overall survival, overall response rate, and duration of response, were also presented. The safety profile was consistent with no new safety signals observed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.66%
Tags
clinical trial
News

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer

Rhea-AI Summary
Merck (MRK) has announced that the FDA has accepted a new supplemental Biologics License Application (sBLA) for KEYTRUDA, in combination with Padcev, for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma. The sBLA is based on data from the Phase 3 KEYNOTE-A39 trial, showing a significant improvement in overall survival and progression-free survival versus chemotherapy. The FDA has set a target action date of May 9, 2024, for review.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
none
-
News

AWS and Accenture Help Merck Use Cloud Technology to Reduce Drug Discovery Time and Accelerate Clinical Trial Development

Rhea-AI Summary
Amazon Web Services (AWS) is working with Accenture to help Merck (MRK) move its IT infrastructure to AWS, accelerate scientific research and discovery, and transform its value chain. Merck is using AWS analytics and AI services across its divisions, including a manufacturing platform to improve product availability and yield. The cloud migration will enable Merck to redirect resources to other strategic programs, with significant IT operational savings already realized.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
clinical trial
-
News

Merck Announces First-Quarter 2024 Dividend

Rhea-AI Summary
Merck (MRK) declares a quarterly dividend of $0.77 per share for Q1 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
dividends
News

Merck’s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older

Rhea-AI Summary
Merck (MRK) announced the results of the Phase 3 trial, STRIDE-3, evaluating V116, the company’s 21-valent pneumococcal conjugate vaccine designed to protect adults. The trial showed that V116 elicited non-inferior immune responses compared to PCV20 for 10 serotypes common to both vaccines in adults 50 years and older. V116 also had a safety profile comparable to PCV20. The results are being presented at the World Vaccine Congress West Coast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
none

FAQ

What is the current stock price of Merck & Co. (MRK)?

The current stock price of Merck & Co. (MRK) is $101.16 as of November 25, 2024.

What is the market cap of Merck & Co. (MRK)?

The market cap of Merck & Co. (MRK) is approximately 256.1B.

What are the main therapeutic areas Merck focuses on?

Merck focuses on several therapeutic areas including cardiometabolic diseases, cancer, and infections. They also have a significant vaccine business and an animal health division.

What is Merck for Mothers?

Merck for Mothers is Merck’s global initiative dedicated to improving maternal health. The program has reached over 30 million women with initiatives that promote safe, high-quality care during pregnancy and childbirth.

What are some of Merck’s key products in oncology?

Merck's oncology portfolio includes KEYTRUDA, an immunotherapy used to treat various cancers, including melanoma. KEYTRUDA has shown significant benefits when used in combination with other therapies.

How significant is Merck’s vaccine business?

Merck has a substantial vaccine business, offering vaccines for pediatric diseases and human papillomavirus (HPV). Their vaccines portfolio is a major contributor to their public health impact.

Where is Merck headquartered?

Merck is headquartered in Rahway, New Jersey, USA.

What percentage of Merck’s sales comes from the United States?

Approximately half of Merck's sales are generated in the United States.

What is Merck's approach to research and development?

Merck invests heavily in research and development with over 2,250 ongoing clinical trials. Their approach focuses on innovative treatments and combination regimens to address complex health challenges.

What recent achievements has Merck announced?

Merck recently surpassed its goal of reaching 25 million women with its maternal health initiative, Merck for Mothers, by reaching over 30 million women. Additionally, they have reported promising results from clinical trials involving KEYTRUDA.

Does Merck collaborate with other companies for research?

Yes, Merck is actively involved in numerous partnerships and collaborative research initiatives to accelerate the development of new therapies.

What is the historical origin of Merck & Co., Inc.?

Merck & Co., Inc. originated from the Merck Group, which was founded in Germany in 1668. The American arm, now an independent company, was established to serve the United States and Canada.

Stock MRK logo
Merck & Co., Inc.

NYSE:MRK

MRK Rankings

#34 Ranked by Market Cap
#933 Ranked by Dividends

MRK Stock Data

256.11B
2.53B
0.06%
79.47%
1.04%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
KENILWORTH